## VRTX: Vertex Pharmaceuticals Incorpor - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.58 indicates fundamental undervaluation. Quality metrics strong (ROE 22%, ROA 12%).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($426.86)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Texas Permanent School Fund Corp Sells 9,892 Shares of Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251216T123405 | Somewhat-Bullish | Relevance: 100%
- Texas Permanent School Fund Corp significantly reduced its stake in Vertex Pharmaceuticals (VRTX) by selling 9,892 shares, representing a 35.4% decrease in its holdings. This divestment comes as company insiders have also been active sellers, with EVP Charles F. Wagner Jr. and Chairman Jeffrey M. Leiden collectively disposing of over 77,000 shares in December. Despite these insider sales and institutional reductions, Vertex Pharmaceuticals recently exceeded Q2 earnings and revenue expectations, maintaining a "Moderate Buy" consensus rating among analysts with an average price target of $498.42.

**2. What's Driving the Market Sentiment Around Vertex Pharmaceuticals Inc?**
- Source: Sahm | 20251216T030959 | Somewhat-Bearish | Relevance: 100%
- Vertex Pharmaceuticals Inc. (NYSE: VRTX) has seen an 11.24% rise in its short interest as a percent of float, with 4.46 million shares sold short, representing 1.98% of available shares. This increase suggests a more bearish sentiment among some investors. However, when compared to its peers, Vertex Pharmaceuticals Inc. still has less short interest on average (1.98% compared to the peer group average of 7.41%).

**3. Corient Private Wealth LLC Cuts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251217T085659 | Somewhat-Bearish | Relevance: 97%
- Corient Private Wealth LLC reduced its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.5% in the second quarter, selling 3,734 shares and leaving them with 102,816 shares valued at $45.77 million. Other institutional investors also made new investments in VRTX shares, while company insiders, including Chairman Jeffrey M. Leiden and EVP Charles F. Wagner, Jr., sold significant portions of their holdings. Analysts have a "Moderate Buy" rating on Vertex Pharmaceuticals with an average price target of $498.42.

**4. Shorepoint Capital Partners LLC Invests $4.08 Million in Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251216T122505 | Somewhat-Bullish | Relevance: 97%
- Shorepoint Capital Partners LLC has acquired a new stake of 10,405 shares in Vertex Pharmaceuticals (NASDAQ:VRTX), valued at approximately $4.08 million. This investment comes amidst significant insider selling, with the Chairman and EVP liquidating shares worth over $35 million in total. Despite these insider transactions, Vertex Pharmaceuticals reported strong quarterly earnings, beating analyst expectations for both EPS and revenue, and maintains an average analyst rating of "Moderate Buy."

**5. eBay price suffers from negative pressures - Forecast today - 17-12-2025**
- Source: Economies.com | 20251217T110818 | Bullish | Relevance: 88%
- eBay Inc. (EBAY) is predicted to decline due to negative pressures, including a short-term descending corrective trend and trading below its 50-day SMA, coupled with bearish divergence in RSI indicators. The forecast suggests a drop towards the pivotal support level of $79.80, as long as resistance at $85.65 remains unchallenged. This analysis indicates an overall bearish outlook for eBay's stock in upcoming trading sessions.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wells Fargo | $515 | $460 | +12% |
| 2025-12-05 | Morgan Stanley | $564 | $516 | +9% |
| 2025-12-03 | Morgan Stanley | $516 | $438 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-12-05 | Morgan Stanley | main | Overweight |
| 2025-12-03 | Morgan Stanley | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($3.52M) |
| Sells | 10 ($11.24M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Capital World Invest: 10.2% (-9.8%)
- Vanguard Group Inc: 9.5% (+1.0%)
- Blackrock Inc.: 8.8% (+1.7%)
- Capital Research Glo: 6.5% (+2.8%)
- JPMORGAN CHASE & CO: 5.1% (+119.3%)

### Key Risks

1. Heavy insider selling: $11M sold (10 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +13%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.58 indicates undervaluation relative to growth. Forward P/E 22.1x stretched relative to 10% growth. Quality metrics strong (ROE 22%, ROA 12%, margin 31%). Balance sheet: strong liquidity (2.4x), low leverage (D/E 0.44), $1.1B free cash flow. Analyst sentiment positive (3 raises, avg +13%). Insider selling cluster ($11.2M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $114.7B |
| Beta | 0.32 |
| 52W Range | $362.50 - $519.68 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.58 |
| Forward P/E | 22.1 |
| Current P/E | 24.3 |
| YoY Growth | 9.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 weakening modestly (-0.9% over 5 days). Below STRENGTH zone by 2.0pp (needs >4.0% for momentum thesis). MRS_5 (-1.0%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 55. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.03% (CS: 60) | Neutral |
| RSI_14 | 55.4 | Neutral |
| MACD Histogram | -0.14 | Bearish |
| vs SMA20 | 1.013x | Above |
| vs SMA50 | 1.042x | Above |
| vs SMA200 | 1.014x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $447.38
- **Stop Loss:** $426.86 (4.6% risk)
- **Target:** $488.42 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 46
- **Position Value:** $20,579.48
- **Portfolio %:** 20.58%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-09 (Est: $5.17)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.58 | $4.80 | +4.9% |
| 2025Q2 | $4.25 | $4.52 | +6.3% |
| 2025Q1 | $4.29 | $4.06 | -5.4% |
| 2024Q4 | $4.02 | $3.98 | -1.0% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*